sarcoma

This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.

Merck forges closer ties with Cancer Research UK

notable pipeline failures, including evofosfamide for advanced soft tissue sarcoma and pancreatic cancer.

Bayer gets clinical data to support $1.5bn Loxo deal

uncontrolled cellular growth that is evident in a wide range of tumours, including infantile fibrosarcoma, thyroid cancer and various soft tissue sarcomas, but collectively account for less than 1% of all
Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

They are seen in a collection of malignancies including colorectal adenocarcinoma, soft tissue sarcoma, infantile fibrosarcoma and cholangiocarcinoma.
Avelumab costs peg back profit at Merck KGaA

sarcoma and pancreatic cancer after phase III study failures.
Merck's pharma unit faces tougher 2017 as fertility boost recedes

Last year, Merck abandoned plans to seek approval of evofosfamide in advanced soft tissue sarcoma and pancreatic cancer after phase III study failures.
Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo. Licensed for use with doxorubicin for soft tissue sarcoma patients. ... The European Commission has granted Lilly's Lartruvo (orlaratumab) marketing authorisation for the first-line treatment of

More from news
Approximately 6 fully matching, plus 47 partially matching documents found.

Europe vs the US: New drug product approvals

Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’ s annual conference.
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’ s annual conference.
Pharma deals during February 2014

for advanced sarcoma.
Interview: Harvey Berger and Timothy Clackson, Ariad

And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Add my company

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...